CALL FOR ABSTRACT

You are invited to submit abstracts for the Emirates Oncology Conference 2017 to be held at Emirates Palace, Abu Dhabi, United Arab Emirates from November 16-18, 2017.

 

Depending on the number and quality of abstracts received, abstracts will be selected for either oral or poster presentation.

 

All submitted abstracts must be conducted online.

 

Abstracts submissions are accepted until the September 30, 2017 18:00 (GMT +4). Any abstract received after the deadline will not be accepted. Upon completion of evaluation, an ‘Accepted’ or ‘Rejected’ message will be sent to authors by email, approximately 14 days after the deadline for submission.

Who Should Submit an Abstract?

  • Physicians
  • Nurses
  • Students
  • Healthcare Quality and Risk Specialists
  • Researchers
  • Other healthcare professionals

ABSTRACT GUIDELINES

Language:

  • All submitted abstracts must be in English

 

Author(s):

  • The content of the abstract is solely the responsibility of the author. The original abstract is reprinted exactly as provided. During submission, it must clearly indicate the name of the presenting author, who will be considered the contact person for all correspondence connected with the submitted abstract.
  • All submitted abstracts need to have the names and surnames of all co-authors, along with their positions in their affiliated institutions.

 

Title & Length:

  • A poster abstract must have a short, specific title (no abbreviations) that clearly indicates the nature of the investigation. It is encouraged that the title is set so as to attract the audience and to hint to the conclusion of the investigation.
  • All abstracts should not exceed 300 words.

 

Content:

  • A well-written poster abstract typically has the following identified sections:
    1. Background/objectives: a brief introduction, which states the problem that you are addressing as well as some background information on the issue. The introduction of the poster abstract should include a very brief background 1-2 statements followed by the objectives of the investigation.
    2. Design and methods: the methodologies, number of test subjects and scientific approach used to conduct the research.
    3. Results: it is expected that authors present data that support their conclusion. Tables and graphs should include explanatory captions.
    4. Conclusions: further areas of research and overall conclusion of the research
    5. Citation: a reference list and acknowledgements, if applicable

 

Case reports will not be accepted. No tables and figures are allowed. 

 

Tips in writing your poster:

  • Make the title dynamic and conclusive, rather than descriptive.
  • Identify your submission category carefully to assure proper consideration.
  • Use generic names. Use trade names only when necessary.
  • Avoid beginning sentences with numerals.
  • Standard abbreviations may be used without definition. Nonstandard abbreviations should be placed in parentheses after the first use of the word or phrase abbreviated.
  • No references, credits or grant support should be included in the poster abstract.
  • No identifying information about patients participating in a study or trial should be used.
  • All abbreviations must be defined before being used as an abbreviation in the text.
  • Proofread poster abstracts carefully to avoid errors before submission. No corrections will be allowed or made once the poster abstract has been submitted.

CO-AUTHOR APPROVAL

The submitting author must verify that all co-authors have read and approved the submission of the poster abstract.

ACCEPTANCE & REJECTION

Upon completion of the evaluation of submitted abstracts, an ‘Accepted’ or ‘Rejected’ email will be sent to authors. Upon acceptance of an author’s poster presentation, the following instructions below are applicable:

  • The presenting author of the poster presentation should confirm their attendance upon receiving the acceptance email within one week.
  • The availability of any sort of grant for registration, travel and/or accommodation will be mentioned in the acceptance email, without any guarantees at the abstract submission stage.
  • Poster authors who confirm presence will receive a poster code based on their category of submission 1 week before the congress. Authors should use the poster code in that email to find their space at the poster area during the congress.
  • Authors need to place the title, author(s), institution if applicable and country at the header of the poster presentation
  • The poster display board dimensions will be 100 CM wide x 120 CM length. All posters need to be constraint to that size and not more.
  • The poster thickness of paper advised is 120 to 150 gsm
  • The boards are made out of cork and posters will be pinned or applied using double-sided taped
  • Presenting authors should mount their poster in the allocated poster display area before the conference lectures initiate, during registration time in the early morning
  • Posters should be left on display during the congress until end of the congress
  • Authors should be available near their posters particularly during allotted timings that will be stated in the acceptance email.

ABSTRACT TRACKS

  • Breast Cancer
  • Lung Cancer
  • GI Malignancies
  • Radiotherapy
  • Urologic Malignancies
  • Gynecologic Malignancies
  • Hematologic Malignancies
  • Pediatric Oncology/Hematology
  • Palliative Care
  • Head & Neck
  • Oncology Nursing
  • Geriatrics oncology
  • Supportive care
Submit Now

Abstract Prizes

  • First authors of successful abstracts will win  FREE CONFERENCE REGISTRATION
  • The principal investigators of five best abstracts will be awarded with TRAVEL GRANTS (AED 2000) and invited for “Oral Presentation”
  • All other successful abstracts will be invited for Poster Display within the conference venue and viewed during poster viewing breaks by conference participants and the reviewers’ team

Clinical research abstracts

  • Verification that your clinical research was approved by an appropriate ethics committee or institutional review board and, if appropriate to the research, informed consent was obtained for all subjects
  • Indicate whether your research is a clinical trial.
  • Indicate Type of trial (phases I, II, or III, correlative, quality-of-life, meta-analysis, prevention, exploratory analysis, or other), Research category (clinical, translational, laboratory-based)
  • Though clinical trial registration is not required for abstract submission, publication, or presentation, certain clinical trials are required to be registered by law and/or prior to journal publication.
  • If a clinical trial is already registered, the First Author will be asked to provide the name of the registry and the trial registration number during the abstract submission process
  • Indicate which author(s) is a principal investigator. The principal investigator is the individual (or individuals) with primary responsibility for the development of the protocol, the conduct of the trial, and the interpretation and dissemination of the trial data

Additional Information

  • Agreement to present your abstract if selected for presentation at the Emirates Oncology Conference
  • Agreement to publish your abstract/s in the proceedings book
  • Agreement to display the abstract poster only if selected by EOC scientific committee
  • Abstracts that are not selected for poster display but approved will be published in the proceedings book only

Criteria for a successful abstract

  • Authors must demonstrate whether or not the research conducted was in any way supported by commercial organizations, including any grants or in-kind donations
  • Do not include acknowledgements or brand names in abstract/s
  • Abstracts should not promote commercial services, companies or products
  • Abstracts should provide material that is relevant to the conference’s learning objectives and suggested topics above
  • Abstracts should provide a detailed description of the scientific methods employed during your research (purpose, methods, results, and conclusion)
  • Abstracts should be presented using scientific terminology and maintaining clarity
  • Clearly state how your research benefits patient safety
  • Do not exceed the word limit allocated
  • Do not include any logos

Reasons for abstract Rejection

  • Lack of authors correspondence and contact details
  • Promotion of commercial services, companies or products
  • Lack of originality in research
  • Lack of sufficient data
  • Poor explanation of methodologies employed during research
  • Re-submitting the same abstract
  • Lack of adherence to Terms, Conditions and Guidelines
  • Abstracts submitted as email messages will NOT be entertained
  • Abstracts submitted on paper or by fax will not be accepted
  • Abstracts without clear relevance to the event’s learning objectives will not be reviewed or considered

Author Agreement

By submitting the abstract, the author/s confirms and agrees to the following:

  • All authors approve submitting this work for display during the conference days and / or presentation if selected.
  • The authors have done the work reported in the abstract and take full responsibility for the contents.
  • The authors transfer all copyright ownership of the abstract to EOC 2017
  • The authors agree to confine their presentation to information in the abstract.
  • At least one person on the abstract author’s list should be available to present the abstract if selected otherwise another one will be selected.
  • The author will immediately notify the EOC 2017 Scientific Committee if they are unable to make a presentation or if the presenting author is changed.
  • The authors guarantee that clinical studies have proceeded with the official permission from the proper authorities.

 

ALL PRESENTERS WILL BE RESPONSIBLE FOR THEIR OWN REGISTRATION FEES, HOTEL AND TRAVEL EXPENSES.